Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 11,301–11,400 of 15,747
Gan, M., Cao, J., Ouyang, Q., Xu, X., Wang, X., Dan, P., Yao, Y., Fu, H., Yao, X., Lin, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07076-z · Cited by 4
“Interestingly, T cells from both naturally infected and vaccinated individuals are capable of recognizing the spike protein of early SARS-CoV-2 variants [20], and these early variants are unable to completely evade the host’s pre-established cellular immune responses [7, 8, 21, 22].”
Miyauchi, K., Usui, J., Shimizu, T., et al. (2025) · CEN Case Reports · doi:10.1007/s13730-025-00999-y · Cited by 2
“The mRNA vaccines developed by Pfizer/ BioNTech (BNT162b2) and Moderna/NIH (mRNA-1273) show 95% and 94.1% efficacy, respectively, in preventing symptomatic COVID-19 after two doses [1–3].”
Influential(2022) · doi:10.1101/2022.05.27.493682 · Cited by 20
Pommerolle, P., Laurent, P., Presne, C., Brazier, F., Jaureguy, M., Poulain, C., Flahaut, G., Mazouz, H., Brochot, É., Choukroun, G. J., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02580-4 · Cited by 3
Kubica, J., Włodarczyk, Z., Stolarek, W., Wojtal, E., Buszko, K., Grzelakowska, K., Kosobucka, A., Krintus, M., Kryś, J., Kubica, A., et al. (2021) · Medical Research Journal · doi:10.5603/mrj.a2021.0052 · Cited by 2
Chen, X., Ye, Y., Li, M., Zuo, T., Xie, Z., Ke, Y., Cheng, H., Hong, L., & Liu, Z. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.27.614859 · Cited by 2
“Lipid nanoparticles (LNPs) have proven to be versatile nanocarriers for delivering nucleic acids in a range of medical applications, including cancer immunotherapy (1, 2), metabolic regulation (3, 4), and prophylactic interventions (5, 6).”
BackgroundExtrahepatic Gene Editing In Vivo Using Organic Solvent‐Free Lipid Nanoparticles
Streiber, M., Liu, N., Simon, L., Adermann, F., Bachmann, V., Gath, L., Hoeppener, S., Schubert, S., Werz, O., Lapinte, V., et al. (2026) · Small · doi:10.1002/smll.202511489 · Cited by 5
The rational design of mRNA vaccine: From empirical method to artificial intelligence-based design
Hu, Y., Pu, C., Liu, B., & Zhang, L. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0478 · Cited by 2
COVID ‐19 mRNA vaccines and myopericarditis
Gnanenthiran, S. R., & Limaye, S. (2022) · Internal Medicine Journal · doi:10.1111/imj.15748 · Cited by 5
Vacunas para COVID-19 - ¿Podemos evitar volver a vivir en un pueblo fantasma?
Rodriguez-Morales, A. J., Mattar, S., V, & Marco González, T. (2021) · Revista Mvz Córdoba · doi:10.21897/rmvz.2350 · Cited by 2
Eosinophilic gastroenteritis following COVID-19 mRNA vaccination
Yoshino, Y., & Tsuboi, K. (2024) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2024_004316 · Cited by 2
Evaluation of some cardiac markers in relation to COVID-19 mRNA vaccine
AL-Eqabi, A., & Al-Azzawi, B. A. (2022) · Journal of Biomedicine and Biochemistry · doi:10.57238/jbb.2022.19395 · Cited by 1
“The results of the study were disagreed with [52,53] it was shown which no clinical studies have reported the incidence of carditis following vaccination against CoV-19 virus.”
Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis
Ouyang, L., Lei, G., & Gong, Y. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2326316 · Cited by 2
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
Gagné, M., Flynn, B. J., Honeycutt, C. C., Flebbe, D. R., Andrew, S. F., Provost, S. J., McCormick, L., Ry, A. V., McCarthy, E. E., Todd, J.-P. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51046-w · Cited by 4
A Brief History of the Science of Vaccine Passports and What the Future Holds
Wilson, K. R. (2024) · Routledge eBooks · doi:10.4324/9781003394006-22 · Cited by 3
COVID-19 vaccine therapeutic trials review: published results and registered protocols
Osman, M., Safer, M., Hechaichi, A., Letaief, H., Dhaouadi, S., Harizi, C., Salah, H. B., Derouiche, S., Bouabid, L., Bougatef, S., et al. (2022) · Journal of Global Health Reports · doi:10.29392/001c.21369 · Cited by 2
Hsieh, M. W., Lai, C., Chang, Y., & Lai, Y. (2024) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000010921 · Cited by 2
A Chronology of the COVID-19 Pandemic in Japan
Yoda, T. (2023) · Science across cultures · doi:10.1007/978-3-031-36331-3_5 · Cited by 2
A Highly Potent SARS-CoV-2 Blocking Lectin Protein
(2021) · doi:10.1101/2021.07.22.453309 · Cited by 2
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127556 · Cited by 3
Pather, S., Charpentier, N., van den Ouweland, F., Rizzi, R., Finlayson, A., Salisch, N. C., Muik, A., Lindemann, C., Khanim, R., Abdul-Jawad, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126165 · Cited by 5
[COVID-19 Vaccination for Cancer Patients: Progress and Preliminary Recommendations].
Wang, L., Xu, Y., Zhang, L., Fan, J., Pan, R., Wang, J., & Wang, M. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.101.18 · Cited by 2
Liu, Y. H., Liu, R., Meng, C., Li, J., Yang, K., Zhang, F., Xia, X., Ye, G., & Yuan, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1873905 · Cited by 2
Bermingham, C., Nafilyan, V., Andrews, N., & Gethings, O. (2023) · medRxiv · doi:10.1101/2023.06.06.23290982 · Cited by 5
“Large clinical trials have been undertaken for all of the vaccines approved in the UK, which found high efficacy against symptomatic disease and severe outcomes [2]–[4].”
BackgroundDissanayake, R., & Wu, Y. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3759421 · Cited by 2
Hu, H., Leng, C., Shu, Y., Lü, P., Wu, F., Liu, J., Zhang, X., Zhou, W., Xiao, Q., Li, Y., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01307-24 · Cited by 2
The Care of the Leukemic Patients in Times of SARS-CoV-2
Karki, N. R., Le, T. T., & Cortes, J. E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01111-0 · Cited by 2
Ghasemi, A., Khodashahi, R., Aliakbarian, M., Khaleghi, E., Razmkhah, B., Vahdatinia, M., Far, M. S., & Bakhti, O. (2022) · Current Drug Safety · doi:10.2174/1574886317666220801122822 · Cited by 2
Enlow, P. T., Thomas, C., Osorio, A. M., Lee, M., Miller, J. M., Pelaez, L., Kazak, A. E., & Phan, T.-L. T. (2024) · Delaware Journal of Public Health · doi:10.32481/djph.2024.03.06 · Cited by 5
Subbarao, S., Copas, A. J., Andrews, N., Gower, C., Bernal, J. L., Ramsay, M. E., & Paranthaman, K. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3922678 · Cited by 2
Interpretation of non-responders to SARS-CoV-2 vaccines using WHO International StandardPreprint
Zeng, Q., Yang, X. Y., Gao, Q., Lin, B., Li, Y., Huang, G., & Xu, Y. (2022) · medRxiv · doi:10.1101/2022.03.31.22273272 · Cited by 2
Age-related heterogeneity in immune responses to SARS-CoV-2 following BNT162b2 vaccination
(2021) · doi:10.21203/rs.3.rs-428630/v1 · Cited by 750
Unagami, K., Yoshikawa, M., Egawa, H., Ohfuji, S., Natori, Y., Oki, R., Mori, T., Hattori, H., Ishiwatari, A., Kanzawa, T., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126221 · Cited by 3
Powelson, I. A., Kaufmann, R. A., Chida, N. M., & Shores, J. T. (2021) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2021.07.002 · Cited by 2
“H IGHLY EFFECTIVE VACCINES for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are now available to the general public.(1,2) However, recent data have demonstrated decreased vaccine efficacy among immunocompromised populations, such as those who have undergone solid organ trans…”
BackgroundDendritic cell-based COVID-19 vaccines: A mini review
Pertiwi, D., Hafiz, I., & Illian, D. N. (2021) · Journal of Research in Pharmacy · doi:10.29228/jrp.78 · Cited by 1
Mitsunaga, T., Ohtaki, Y., Seki, Y., Yoshioka, M., Mori, H., Suzuka, M., Mashiko, S., Takeda, S., & Mashiko, K. (2021) · medRxiv · doi:10.1101/2021.07.18.21260579 · Cited by 3
Building vaccine and biotherapeutics manufacturing capacity in Africa: a practical approach
Haakuria, V. M., Munezero, P. C., Valdes, R., et al. (2025) · Discover Medicine · doi:10.1007/s44337-025-00313-w · Cited by 2
“COVID-19 vaccines (SpikeVax and Comirnaty) were developed in an unprecedented short period with both vaccines producing effectiveness of 94.1% and 95% respectively [55–57].”
InfluentialMosqueda, J., Hernández-Silva, D. J., Vega‐López, M. A., Vega-Rojas, L. J., Beltrán, R., Velasco-Elizondo, A., Ramírez‐Estudillo, M. D. C., Fragoso-Saavedra, M., Pérez-Almeida, C., Hernández, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1276950 · Cited by 2
Manuel, O. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.018 · Cited by 2
“Among them, mRNA-based vaccines (BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)) seem to be the most efficacious in preventing symptomatic infection, need for hospitalization and death [1,2].”
Nshimiyimana, S., Kimotho, J. H., & Ngugi, C. W. (2025) · World s Veterinary Journal · doi:10.54203/scil.2025.wvj37 · Cited by 3
Air Pollution and COVID-19 Severity
Alsina-Pujols, M., & Castelló, J. V. (2025) · Environmental and Resource Economics · doi:10.1007/s10640-025-01007-8 · Cited by 3
“In fact, Polack et al. ( 2020) show evidence that the early-stage protection from the vaccine begins twelve days after the first dose.”
Recent Update of COVID-19 Vaccines
Jadaan, S. A., & Khan, A. W. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.045 · Cited by 2
Patient perspectives of pain mitigation strategies for adult vaccine injections
Cull, K., Bowles, S. K., MacDonald, N. E., McNeil, S., Taylor, B. A., Slayter, K., Steenbeek, A., Taddio, A., Bucci, L. M., & Isenor, J. E. (2021) · Canadian Journal of Pain · doi:10.1080/24740527.2021.1967113 · Cited by 2
Infectious Disease Spreading Fought by Multiple Vaccines Having a Prescribed Time Effect
Colombo, R. M., & Garavello, M. (2022) · Acta Biotheoretica · doi:10.1007/s10441-022-09452-4 · Cited by 3
“Class 2 First: for t ∈ [30 , 380], p 1 ( t ) = 0 and p 2 ( t ) = 1 as long as S 2 ( t ) > 0; for t ∈ [380 , 730], p 1 ( t ) = 1 and p 2 ( t ) = 0 as long as S 1 ( t ) > 0.”
BackgroundInfluentialNonchromatographic Purification of Synthetic RNA
McClain, I. M., Dagci, H., & Royzen, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_84 · Cited by 2
Mehta–Shah, N., Bartlett, N. L., Kahl, B. S., Watkins, M. P., Dubois, A., Schmelzle, G., Waqar, S. N., Ballman, C., Wan, F., & Farnsworth, C. W. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2038377 · Cited by 2
Jasem, Z. A., Manee, F., Alqattan, D., & Smith, T. M. (2024) · Medical Principles and Practice · doi:10.1159/000539781 · Cited by 3
The Relationship Between Long Covid Symptoms and Vaccination Status in COVID‐19 Survivors
Öztürk, F., Emiroğlu, C., & Aypak, C. (2025) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.70004 · Cited by 2
A novel platform for engineered AAV-based vaccines
Babutzka, S., Gehrke, M., Παπαδοπούλου, Α., Diedrichs‐Möhring, M., Giannaki, M., Hennis, L., Föhr, B., Kooyman, C., Osterman, A., Yannaki, E., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101418 · Cited by 2
Thongkum, W., Thongheang, K., & Tayapiwatana, C. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44070195 · Cited by 2
(2021) · doi:10.1101/2021.07.19.21260762 · Cited by 2
“In our cohort, 42% had detectable anti-S antibodies after two doses of an approved vaccine compared to 91–100% in healthy individuals in phase I/II trials.(2,10) Even when seroconversion occurs, the protective humoral response may be limited.”
BackgroundKafle, S., Montoya, B., Tang, L., Tam, Y. K., Muramatsu, H., Pardi, N., & Sigal, L. J. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102279 · Cited by 2
COVID-19 Vaccine Hesitancy the United States
Kekeh, M. A., Lucero, L. M., & Akpinar‐Elci, M. (2022) · Springer eBooks · doi:10.1007/978-3-031-09432-3_22 · Cited by 2
González-Sánchez, Ó. A., González-Ortiz, L. J., Sánchez-Peña, M. J., Pulido, H. G., Cervantes, O., Márquez‐Sandoval, F., Hernández‐Bello, J., Casillas, N., & Muñóz-Valle, J. F. (2023) · Vaccines · doi:10.3390/vaccines11040719 · Cited by 2
“Suthar, M.S.; Arunachalam, P.S.; Hu, M.; Reis, N.; Trisal, M.; Raeber, O.; Chinthrajah, S.; Davis-Gardner, M.E.; Manning, K.; Mudvari, P.; et al. Durability of immune responses to the BNT162b2 mRNA vaccine.”
BackgroundInfluentialO’Neill, A., Kala, M. P., Tan, C. W., Saron, W. A. A., Mantri, C. K., Rathore, A. P. S., Wang, L., & John, A. L. S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.09.507250 · Cited by 2
“Among the first vaccines approved against SARS-CoV-2 were mRNA-based vaccines, which initial analyses showed can be >90% effective a few weeks following the vaccine protocol completion 6,11 .”
BackgroundInfluentialStreiber, M., Schubert, U. S., & Traeger, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115023 · Cited by 7
Winokur, P. L., Diya, O., Fitz-Patrick, D., Dever, M. E., Gayed, J., Lockhart, S. P., Xu, X., Zhang, Y., Bangad, V., Wadsworth, L. T., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag026 · Cited by 3
“BNT162b2, a messenger RNA (mRNA) vaccine encoding the SARS-CoV-2 spike protein [2], demonstrated 95%‒100% efficacy after the two 30 μ g dose primary series [3, 4].”
Self-citationMarkers of memory CD8 T cells depicting the effect of the BNT162b2 mRNA COVID-19 vaccine in JapanPreprint
Kondo, H., Kageyama, T., Tanaka, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-936363/v1 · Cited by 2
Massonnaud, C., Roux, J., Vittoria Colizza, A., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3975347 · Cited by 2
Aerosol and Droplet Generation from Open Rhinoplasty: Surgical Risk in the Pandemic Era
Ye, M. J., Campiti, V. J., Falls, M. E., Howser, L. A., Sharma, D., Vadhul, R. B., Burgin, S. J. M., Illing, E. A., Ting, J. Y., Koehler, K. R., et al. (2021) · Facial Plastic Surgery & Aesthetic Medicine · doi:10.1089/fpsam.2021.0157 · Cited by 2
Gutlapalli, S. D., Ganipineni, V. D. P., Danda, S., Fabián, D., Okorie, I. J., Paramsothy, J., Kailayanathan, T., Umyarova, R., Aviles, C., Garlapati, S. K. P., et al. (2023) · Cureus · doi:10.7759/cureus.36809 · Cited by 3
“One of the reasons for the success of SARS-CoV-2 vaccines is considered to be the ease of generating nAbs targeting the immunodominant epitopes on the RBD of the S1 subunit of the spike protein [14-19].”
BackgroundChronic Pulmonary Complications After COVID-19
Mansour, T. M. M., teleb, A. A. E. A., Abdalla, H., Abdelnaser, M. M., El-baroudy, M. M., & Mohammed, H. A. E.-M. (2025) · CHEST Pulmonary · doi:10.1016/j.chpulm.2025.100208 · Cited by 2
What is the status of nucleic acid contamination in 2019-nCOV vaccination sites? Can it be avoided?
Li, Z., Zhang, B., Wu, X., Yang, M. J., Zhang, Q., Xiang, G., Chen, Y., Zeng, L., Tayier, D., Zhang, W., et al. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821001394 · Cited by 2
Gabashvili, I. S. (2021) · medRxiv · doi:10.1101/2021.06.28.21256779 · Cited by 1
“Our data will be compared to local and systemic reactions (reactogenicity) of the COVID-19 vaccines reported by participants of clinical trials [7-14] and participants of vsafe or other prospective studies [15,16] 0 to 7 days after the injection.”
ResultKlingel, H., Krüttgen, A., Imöhl, M., & Kleines, M. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.1.60 · Cited by 4
“Although the new technology and the fast development of mRNA vaccines against SARS-CoV-2 have given rise to safety concerns, several clinical trials have demonstrated acceptable safety with predominately mild to moderate adverse reactions [7,8,11,12,15,17-22].”
(2021) · doi:10.1101/2021.05.26.445422 · Cited by 2
“In addition, the obtained information concerning more dangerous (in terms of binding affinity) VoC may help in planning future antibodies [1, 6] and/or rounds of vaccination by using new vaccines based on a cocktail of the newly identified spike sequences (in the form of mRNA [4, 5] or proteins/subdomains [7–9]) showi…”
BackgroundMyocarditis and Pericarditis Related to mRNA COVID-19 Vaccination: A Case Report
López, E. M. P., Rangel‐Sousa, D., & Jorge, N. R. (2023) · Current Drug Safety · doi:10.2174/1574886318666230329123459 · Cited by 2
COVID-19 : doit-on se faire vacciner ? Fantasme du risque et risque fantasmé
Hansen, J.-C., Carpentier, J.-P., & Martin, R. (2021) · Médecine de Catastrophe - Urgences Collectives · doi:10.1016/j.pxur.2021.01.001 · Cited by 3
SARS-CoV-2 Immunity: Review of Immune Response to Infection and Vaccination
Ahmad, R. (2021) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v20i5.55398 · Cited by 2
Thuy, P. X., Trang, H. T. X., Choi, J., Lee, J.-B., Park, S., Kim, B., Lim, Y.-S., & Hwang, S. B. (2023) · Journal of Virology · doi:10.1128/jvi.01737-23 · Cited by 4
Meggiolaro, A., Schepisi, M. S., Farina, S., Castagna, C., Mammone, A., Siddu, A., Stefanelli, P., Boccia, S., & Rezza, G. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4147520 · Cited by 2
Fujieda, K., Tanaka, A., Kikuchi, R., Takai, N., Saito, S., Yasuda, Y., Fujita, T., Kato, M., Furuhashi, K., & Maruyama, S. (2023) · Vaccines · doi:10.3390/vaccines11010134 · Cited by 2
Cooper, D., Harmon, D., Alemayehu, C., Levy, J. A., Gastañaduy, M., Fort, L. B., & McCoin, N. S. (2023) · Western Journal of Emergency Medicine · doi:10.5811/westjem.57449 · Cited by 2
Self-citationArena, R. A. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.12.035 · Cited by 2
“Evidence overwhelmingly indicates COVID-19 vaccination is safe and highly effective in preventing COVID-19.(7) As beneficial as healthy living medicine is, there is no credible evidence or hypothesis to support adoption of healthy living behaviors as a replacement for vaccination; this is a reckless viewpoint.”
BackgroundLee, H., Jeong, N., Park, M., Lim, E., Kim, J., Won, H., Kim, C.-J., Park, S. M., & Choi, N. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.03.015 · Cited by 3
Higher Vaccination Rate Predicts Reduction in SARS-CoV-2 Transmission across the United StatesPreprint
Au, J. (2021) · medRxiv · doi:10.1101/2021.11.14.21266325 · Cited by 2
“Correlation Matrix Variables (1) (2) (3) (4) (5) (6) (7) (1) Incidence 1.”
BackgroundResultInfluentialGhani, H., Ahmad, L., Sharif, H., Wong, J., Bagol, S. H., Alikhan, M. F., Taib, S., Tan, C. W., Zhu, F., Ong, X. M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-067020 · Cited by 2
Exploring the Immune Response to COVID ‐19 Vaccines in Dialysis and Transplant Patients
You, H. W., Lim, S. K., Kong, B. H., Cheng, S. F., Rajasuriar, R., & You, H. W. (2025) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.70066 · Cited by 2
“COVID-19 vaccine is one of the most important protective measures against COVID-19 infection [8, 9].”
Impact of COVID‐19 pandemic on EJI and the extended immunological community
Santo, J. P. D. (2021) · European Journal of Immunology · doi:10.1002/eji.202170016 · Cited by 2
Kossyva, N., Spanakis, M., Borboudaki, L., Stylianakis, D., Rikos, N., Rovithis, M., Perdikogianni, C., Linardakis, M. K., & Symvoulakis, E. K. (2026) · Healthcare · doi:10.3390/healthcare14091167 · Cited by 3
“Randomized trials for COVID-19 vaccines demonstrated approximately 95% efficacy and protection against severe disease [36–38].”
Wagenhäuser, I., Reusch, J., Gabel, A., Mees, J., Nyawale, H. A., Frey, A., Lâm, T., Schubert‐Unkmeir, A., Dölken, L., Kurzai, O., et al. (2023) · medRxiv · doi:10.1101/2023.02.26.23286402 · Cited by 2
Chalouni, M., Loubet, P., Lhomme, E., Ninove, L., Barrou, B., Blay, J., Hourmant, M., Seze, J. D., Laville, M., Laviolle, B., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09861-5 · Cited by 2
Evaluation of autoantibody profile in healthy subjects after mRNA vaccination against COVID-19
Fiorelli, D., Caruso, V., Belardi, R., Bernardini, S., & Nuccetelli, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110592 · Cited by 2
Antiviral potential of nanomaterials: Novel solutions for emerging challenges
Azab, W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821637-8.00003-1 · Cited by 2
Gańczak, M., Korzeń, M., Sobieraj, E., Goławski, J., Pasek, O., & Biesiada, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19053111 · Cited by 2
“Our results provided evidence to support other studies, both RCTs and those conducted in the community, of a lower occurrence of side effects in older individuals [17,19,20,29].”
BackgroundResultInfluentialLearning from cancer to address COVID-19
Oláh, E. (2023) · Biologia Futura · doi:10.1007/s42977-023-00156-5 · Cited by 2
Aripov, T., Wikler, D. I., Asadov, D. A., Tulekov, Z., Murzabekova, T., & Münir, K. (2022) · BMC Medical Ethics · doi:10.1186/s12910-022-00764-1 · Cited by 3
Mirioğlu, Ş., Kazancıoğlu, R., Cebeci, E., Eren, N., Şakacı, T., Alagöz, S., Tuğçu, M., Tuğlular, S., Sümbül, B., Seyahi, N., et al. (2023) · The Nephron journals/Nephron journals · doi:10.1159/000528170 · Cited by 3
Medium-term scenarios of COVID-19 as a function of immune uncertainties and chronic disease
(2023) · doi:10.1101/2023.03.08.23287004 · Cited by 2
“[2, 3, 4]), and progress toward more broadly protective immunization continues (i.”
Pre-vaccination seroprevalence of SARS-CoV-2 antibodies in the Volta Region, Ghana
Aninagyei, E., Ayivor-Djanie, R., Gyamfi, J., Aboagye, M. E., Kpeli, G. S., Ampofo, W., Gyapong, J. O., & Duedu, K. O. (2024) · IJID Regions · doi:10.1016/j.ijregi.2024.01.007 · Cited by 2
Choueiri, T. K., Labaki, C., Bakouny, Z., Hsu, C., Schmidt, A. L., Lopes, G. D. L., Jr., Hwang, C., Singh, S. R. K., Jani, C., Weissmann, L. B., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4089485 · Cited by 2
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.